Page last updated: 2024-11-12
f21
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 11485425 |
| CHEMBL ID | 177749 |
| SCHEMBL ID | 21067750 |
| MeSH ID | M0232390 |
Synonyms (10)
| Synonym |
|---|
| (3r)-3-(fluoromethyl)-7-(thiomorpholin-4-ylsulfonyl)-1,2,3,4-tetrahydroisoquinoline |
| F21 , |
| DB07739 |
| (r)-3-fluoromethyl-7-(thiomorpholine-4-sulfonyl)-1,2,3,4-tetrahydro-isoquinoline |
| bdbm50163110 |
| CHEMBL177749 , |
| '3-fluoromethyl 7-thiomorpholinosulfonamide 1,2,3,4-tetrahydroisoquinoline' |
| Q27096957 |
| SCHEMBL21067750 |
| PD005507 |
Protein Targets (2)
Inhibition Measurements
Biological Processes (3)
Molecular Functions (2)
Ceullar Components (1)
Bioassays (3)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID239480 | In vitro binding affinity against recombinant human Phenylethanolamine N-methyl-transferase expressed in Escherichia coli using [methyl-3H]-AdoMet | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
| Nanomolar inhibitors of CNS epinephrine biosynthesis: (R)-(+)-3-fluoromethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinolines as potent and highly selective inhibitors of phenylethanolamine N-methyltransferase1. |
| AID238890 | In vitro binding affinity against rat Alpha-2 adrenergic receptor using [3H]clonidine | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
| Nanomolar inhibitors of CNS epinephrine biosynthesis: (R)-(+)-3-fluoromethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinolines as potent and highly selective inhibitors of phenylethanolamine N-methyltransferase1. |
| AID244214 | Ratio of affinity for Alpha-2 adrenergic receptor to that of Phenylethanolamine N-methyl-transferase | 2005 | Journal of medicinal chemistry, Mar-24, Volume: 48, Issue:6
| Nanomolar inhibitors of CNS epinephrine biosynthesis: (R)-(+)-3-fluoromethyl-7-(N-substituted aminosulfonyl)-1,2,3,4-tetrahydroisoquinolines as potent and highly selective inhibitors of phenylethanolamine N-methyltransferase1. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 65.32
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 65.32 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 4.36 (4.65) | | Search Engine Demand Index | 185.63 (26.88) | | Search Engine Supply Index | 3.55 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |